Overexpression of YB1 C-terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK-BR-3 breast cancer xenograft mouse model

Jian-hong Shi1,#, Nai-peng Cui2,#, Shuo Wang1, Ming-zhi Zhao2, Bing Wang2, Ya-nan Wang3 and Bao-ping Chen2

1 Central Laboratory, Hebei Laboratory of Mechanism and Procedure of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, China
2 Department of Oncology, Affiliated Hospital of Hebei University, Baoding, China
3 Department of Pathology, Affiliated Hospital of Hebei University, Baoding, China

Keywords
angiogenesis; breast cancer; C-terminal domain; proliferation; SK-BR-3; Y-box-binding protein 1

Correspondence
J.-h. Shi, Central Laboratory, Affiliated Hospital of Hebei University, Baoding 071000, China
Fax: 86-312-5981629
Tel: 86-312-5981736
E-mail: shijianhong@hbu.edu.cn

#These authors contributed equally to this work.

(Received 1 September 2015, revised 27 November 2015, accepted 29 November 2015)
doi:10.1002/2211-5463.12004

Y-box-binding protein 1 (YB1) is a multifunctional transcription factor with vital roles in proliferation, differentiation and apoptosis. In this study, we have examined the role of its C-terminal domain (YB1 CTD) in proliferation, angiogenesis and tumorigenicity in breast cancer. Breast cancer cell line SK-BR-3 was infected with GFP-tagged YB1 CTD adenovirus expression vector. An 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) proliferation assay showed that YB1 CTD decreased SK-BR-3 cell proliferation, and down-regulated cyclin B1 and up-regulated p21 levels in SK-BR-3 cells. YB1 CTD overexpression changed the cytoskeletal organization and slightly inhibited the migration of SK-BR-3 cells. YB1 CTD also inhibited secreted VEGF expression in SK-BR-3 cells, which decreased SK-BR-3-induced EA.hy926 endothelial cell angiogenesis in vitro. YB1 CTD overexpression attenuated the ability of SK-BR-3 cells to form tumours in nude mice, and decreased in vivo VEGF levels and angiogenesis in the xenografts in SK-BR-3 tumour-bearing mice. Taken together, our findings demonstrate the vital role of YB1 CTD overexpression in inhibiting proliferation, angiogenesis and tumorigenicity of breast cancer cell line SK-BR-3.

Breast cancer is the most common type of cancer in women with high incidence and mortality, which is mostly due to rapid tumour progression and metastatic spread [1]. Like the majority of solid tumours, breast cancer requires the growth of new blood vessels in order to provide itself with continuous supply of oxygen and nutrients. This necessity for new blood vessel formation in turn could be used as an anticancer treatment strategy and in developing new therapies directed against tumour vasculature [2].

Angiogenesis is the formation of new blood vessels from pre-existing vasculature, which is controlled by proangiogenic factors (such as vascular endothelial growth factor [VEGF], platelet-derived growth factor [PDGF] and epidermal growth factor [EGF]) and antiangiogenic factors (such as angiotatin and endostatin) [3,4]. Indeed, the VEGF signal-transduction pathway has been implicated in breast cancer pathogenesis, and anti-VEGF therapy acting on tumour vasculature has been used for breast cancer therapy [5].

Abbreviations
CCL5, Chemokine ligand 5; CSD, cold-shock domain; CTD, C-terminal domain; DAPI, 4',6-diamidino-2-phenylindole; DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, Fetal bovine serum; MMP-13, Matrix metalloproteinase-13; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; VEGF, vascular endothelial growth factor; VSMCs, vascular smooth muscle cell; YB1, Y-box-binding protein 1.
Y-box-binding protein 1 (YB1) is a member of the conserved cold-shock domain (CSD) family; and participates in proliferation, differentiation, metastasis and drug resistance [6]. Although the role of YB1 in tumorigenesis has been explored over the years in various models, it is still far from being completely deciphered. It has been shown that YB1 acts as an oncogene with important functions in tumour proliferation and progression [7–12]. YB1 also exhibits pleiotropic functions in promoting different cellular processes like migration and invasion [13–15]. Human YB-1 protein consists of three functional domains: alanine- and proline-rich N-terminal A/P domain, highly conserved cold-shock domain (CSD), and C-terminal domain (CTD) [16,17]. YB1 binds to 5’-CTGATTGG-3’ motif (so-called Y-box) or inverted CCAAT box-binding domain via CSD domain, and regulates the expression of many different genes [18]. Furthermore, in our previous studies, we have demonstrated that YB1 interacts with GGCGGG motif (known as GC box) via CTD domain in vascular smooth muscle cell (VSMC) proliferation and differentiation-related gene promoter, which promotes VSMC differentiation [19,20]. In addition, VSMC and vascular endothelial cells are the most important components of vasculature and tumour angiogenesis [21]. Therefore, in this study, we sought to further investigate the role of YB1 CTD in breast cancer cell proliferation, induced endothelial cell tube formation, as well as angiogenesis in mouse model.

Materials and methods

Cell culture and cell lines

Human breast cancer cell line SK-BR-3 and human umbilical vein cell line EA.hy926 were obtained from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Shanghai, China. SK-BR-3 and EA.hy926 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FBS in a humidified atmosphere with 5% CO₂ at 37 °C.

Adenovirus expression vector construction

The GFP-YB1 CTD fusion protein expression plasmid was generated by inserting the human YB1 CTD (amino acids 125–324) coding region into a pEGFP vector (Clontech Laboratories, Palo Alto, CA, USA) using primers 5’-tga caagcttcacaggtcctggtggttcc-3’ (sense) and 5’-taggtcagccttaacctgcctgc-3’ (antisense). For adenovirus expression vector construction, coding region of GFP or GFP-YB1 CTD fusion protein (harbouring GFP and human YB1-coding region for amino acids 125–324) [20] were cloned into the pAD/CMV/V5-DEST vector (Invitrogen, Carlsbad, CA, USA) to create adenovirus Ad-GFP or Ad-GFP-YB1 CTD using the following primers: 5’-cactggattcggagaggag-3’ (sense) and 5’-taatcattcagaggcctgc-3’ (antisense). Resulting constructs were packaged in 293A cells (Invitrogen) by transfection with Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions.

Small interfering RNA (siRNA) transfection

Small interfering RNA targeting YB1 (si-YB1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Transfection was performed using Lipofectamine reagent (Invitrogen) following the manufacturer’s instructions. Cells were harvested 48 h after transfection and followed by MTS proliferation analysis and western blotting.

Western blotting

For western blotting analysis, crude proteins (100 µg) were extracted from SK-BR-3 breast cancer cells, resolved by SDS/PAGE and transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Membranes were blocked with 5% milk in Tris-buffered saline with Tween 20 for two hours at 37 °C; and then, incubated overnight at 4 °C with the following primary antibodies: rabbit anti-YB1 (ab76149, Abcom, Cambridge, MA, USA), rabbit anti-p21 (sc-397, Santa Cruz), rabbit anti-cyclin B1 (1495-1, Epitomics, CA, USA), rabbit anti-cyclin D1 (2261-1, Epitomics), mouse anti-GFP (sc-390394, Santa Cruz) or mouse anti-β-actin (sc-47778, Santa Cruz). After incubation with the appropriate secondary antibody [goat anti-(mouse IgG-HRP), sc-2005, Santa Cruz or goat anti-(rabbit IgG-HRP), sc-2004, Santa Cruz], immunoreactive signal of antibody-antigens was visualized using the Immobilon™ Western Chemiluminescent HRP Substrate (Millipore Corporation).

MTS cell proliferation assay

A commercially available CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was used to evaluate cell proliferation. In brief, approximately 1 × 10⁴ SK-BR-3 breast cancer cells were seeded in 96-well plates and infected with Ad-GFP or Ad-GFP-YB1 CTD for 48 h. Next, 20 µL of MTS reagent were added to each well, and the plate was incubated in the dark for 2 h before detection. Absorbance was measured using a Biotek Epoch Spectrophotometer (Bio Tek Instruments, Inc., Winooski, VT, USA) at 490 nm.
Flow cytometry

The SK-BR-3 breast cancer cells were infected with Ad-GFP or Ad-GFP-YB1 CTD vectors for 48 h for flow cytometry analysis. Then, cells were harvested by trypsinization, fixed and stained with propidium iodide (PI). Cells that demonstrated less than the diploid content of DNA were excluded from the measurement of cell percentages in each cell cycle phase. Cell cycle profile was determined with BD FACSCALIBUR flow cytometer and BD CellQuest™ pro software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The experiment was independently repeated three times.

Actin cytoskeleton staining

To analyse the actin cytoskeleton, SK-BR-3 breast cancer cells were infected with Ad-GFP or Ad-GFP-YB1 CTD for 48 h, fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 at room temperature for 10 min. Thereafter, cells were incubated with TRITC-phalloidin in the dark. Staining with 4',6-diamidino-2-phenylindole (DAPI) was used to visualize nuclear localization. Fluorescence microscopy was performed using the BX53 Microscope Systems (Olympus, Japan).

Cell migration assay

Cell migration was assessed using a cell-wounding assay. Briefly, SK-BR-3 cells were infected with pAd-GFP or pAd-GFP-YB1 CTD vectors for 48 h and grown to 100% confluence on glass slides. Then, cells were scraped off the slides with a cell scraper and were treated with 2 µg·mL⁻¹ mitomycin C (Solarbio Life Sciences, Beijing, China) and incubated in DMEM containing 10% FBS at 37 °C. The experiment was terminated 48 h later. Cells were fixed with methanol and photomicrographs of final wounds were taken for each group. Cell migration activity was expressed as the wound healing area in each field and as the percentage of control. The experiment was independently repeated three times.

Tube formation assay

To examine the effect of YB1 CTD on angiogenesis in vitro, tube formation assay was performed as previously described (47). Briefly, 24-well cluster tissue culture dishes were coated with 100 µL of 10 mg·mL⁻¹ chilled Matrigel (Corning, Bedford, IL, USA) and incubated for 30 min at 37 °C. EA.hy926 cells were pretreated with conditional medium from SK-BR-3 cells infected with Ad-GFP or Ad-GFP-YB1 CTD for 24 h, and were then seeded onto solidified gels at a density of 10⁵ cells per well in 0.5 mL GFP-CM or GFP-YB1 CTD-CM medium. After 8 h of incubation, total lengths of tube-like structures in five randomly selected microscopic fields per well were determined by phase-contrast microscopy, and quantified using image-pro plus software 6.0 (Media Cybernetics, Inc., Rockville, MA, USA).

Conditioned media collection

For obtaining conditioned media, SK-BR-3 breast cancer cells were infected with pAd-GFP or pAd-GFP-YB1 CTD vectors for 24 h in complete media conditions. Thereafter, media was removed and plates were washed twice in DMEM with 0.5% FBS; and incubated for another 24 h in DMEM with 0.5% FBS. Subsequently, GFP-overexpressing SK-BR-3-conditioned media (GFP-CM) and GFP-YB1 CTD-overexpressing SK-BR-3-conditioned media (GFP-YB1 CTD-CM) were collected and stored at 4 °C until further use.

ELISA assay

ELISA assay for quantitative estimation of VEGF in SK-BR-3 cell culture medium was performed using human VEGF Neobioscience ELISA Kits (Neobioscience Technology, Shenzhen, China) according to manufacturer’s instructions. In brief, cell media were added into each well (100 µL per well) and incubated at 37 °C for 90 min. Then, wells were washed, and biotinylated antibody solution (100 µL per well) was added for another 60 min at 37 °C. Next, wells were washed, 100 µL of streptavidin-HRP working solution was added into each well, and incubated in the dark at 37 °C for 30 min. Following washing, TMB (100 µL per well) was added and wells were incubated for 10 min in the dark. Finally, stop solution was added and absorbance was measured using a Biotek Epoch Spectrophotometer (Bio Tek Instruments, Inc.) at 490 nm.

Nude mice subcutaneous injection

For in vivo experiments, 4-6-week-old female BALB/c-nu mice were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China). All mice were bred and housed in a specific pathogen-free environment at Hebei University.
Laboratory Animal Research Center, Baoding, China. All procedures performed in studies involving animals were carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and the ethical standards of Animal Research Ethics Committee of Hebei University. A cell suspension of 100 µL of 1 × PBS containing 5 × 10^6 SK-BR-3 cells was subcutaneously injected into the right mammary fat pad of nude mice. Each experimental group consisted of six mice. Mice weight and size of the formed tumour was monitored closely; and measured every 2 days. Tumour volume was estimated according to the formula: Volume = 1/2 × a × b^2, where (a) and (b) represents the largest and smallest diameters of the tumour, respectively. Mice were sacrificed at day 14 after injection. Tumours were harvested, measured and photographed.

**Immunohistochemistry**

Tumours from nude mice were fixed and sliced into 4-µm-thick sections. A manual immunohistochemical procedure was performed. In brief, after deparaffinization in xylene and rehydration in graded ethanol, endogenous peroxidase was blocked with 3% aqueous H2O2 for 25 min; and then, heat-induced antigen retrieval was accomplished by immersing slides in 10 mM citrate buffer with pH 6 at 120 °C for 10 min. Next, slides were incubated with rabbit anti-CD31 polyclonal antibody (Cat No. NPB1-71663, dilution: 1 : 50, Novusbio, CO, USA) and rabbit anti-VEGF polyclonal antibody (Cat No. 19003-1-AP, dilution: 1 : 50, Proteintech, Chicago, IL, USA) overnight at 4 °C. Then, slides were washed four times and processed with a ready-to-use HRP Anti-Rabbit Kit (Cat No. KT1005a, Abgent Inc., San Diego, CA, USA) for 30 min at room temperature; and finally developed with 3,3′-diaminobenzidine (DAB) as chromogen and counterstained with haematoxylin. Results were reviewed independently by two pathologists. For negative controls, slides were treated with nonimmune serum instead of the primary antibody. The expressions of CD31 and VEGF were determined using a semiquantitative visual approach. Immunostaining scoring was performed while blinded to animals’ information and outcomes. Each sample was assigned to one of the following categories: 0 (0–25%), 1 (26–50%), 2 (51–75%) or 3 (76–100%). The intensity of immunostaining was determined as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). Immunostaining score formula = score of positive cell percentage × score of staining intensity.

**Statistical analysis**

Data are presented as histograms of means ± SEM for three or more independent experiments. Statistical analyses were performed by spss 16.0 software using Student’s t test or one-way ANOVA according to the number of groups compared. A two-way ANOVA and Bonferroni post-tests were performed for the growth curve. Differences were considered significant at P < 0.05.

**Results**

**YB1 CTD decreases SK-BR-3 breast cancer cell proliferation**

One of the aims of this study was to investigate whether YB1 CTD could regulate proliferation in breast cancer cells. For this purpose, human SK-BR-3 breast cancer cells were infected with different amounts of Ad-GFP or Ad-GFP-YB1 CTD vectors for 48 h and western blotting and MTS cell proliferation assay were performed. As shown in Fig. 1A and B, cyclin B1 protein level decreased, p21 protein level increased, and cell proliferation activity significantly repressed in YB1 CTD-overexpressing SK-BR-3 cells in a dose-dependent manner. To further identify role of YB1 in SK-BR-3 breast cancer cell proliferation, endogenous YB1 was knocked down using specific siRNA targeting human YB1. Knockdown of endogenous YB1 resulted in reduced cyclin B1 protein level and decreased proliferation activity in SK-BR-3 breast cancer cells (Fig. 1C and D). These results indicate that overexpression of YB1 CTD repressed SK-BR-3 cell proliferation and proliferation-related marker cyclin B1 expression which may due to competition for endogenous YB1.

**YB1 CTD regulates SK-BR-3 breast cancer cell cytoskeleton and migration**

Phalloidin staining and wound healing assay were performed to evaluate the role of YB1 CTD on SK-BR-3 cytoskeleton and motility. SK-BR-3 breast cancer cells were infected with Ad-GFP or Ad-GFP-YB1 CTD for 48 h. Then, cells were fixed and stained for F-actin with TRITC-phalloidin. As shown in Fig. 2(A), both Ad-GFP and Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells displayed similar actin-rich protrusions. However, F-actin stress fibres appeared thicker and condensed around the nucleus in Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells, suggesting the role of YB1 CTD in actin organization. Furthermore, compared with control cells, Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells have shown a strong reduction in microtubule extension to the cell periphery. Subsequently, wound healing assay has shown that Ad-GFP-YB1 CTD overexpression slightly inhibited SK-BR-3 cell migration ability (Fig. 2B). Collectively,
these results suggest that YB1 CTD alters cytoskeleton organization and inhibits migration in SK-BR-3 cells.

**YB1 CTD inhibits VEGF expression and SK-BR-3 breast cancer cell-induced angiogenesis in vitro**

Secreted VEGF expressions in Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells were examined to determine the role of YB1 CTD in antiangiogenesis signalling in breast cancer cells. SK-BR-3 breast cancer cells were infected with Ad-GFP or Ad-GFP-YB1 CTD for 48 h, and Ad-GFP-overexpressing SK-BR-3-conditioned media (GFP-CM) and Ad-GFP-YB1 CTD-overexpressing SK-BR-3-conditioned media (GFP-YB1 CTD-CM) were collected to detect secreted VEGF expression levels by ELISA. As shown in Fig. 3(A), Ad-GFP-YB1 CTD overexpression significantly decreased secreted VEGF expression levels.

Endothelial cell transwell migration assay was performed to investigate the role of YB1 CTD in SK-BR-3 breast cancer cell-induced angiogenesis. For this purpose, chemotactic motility of EA.hy926 cells to Ad-GFP or Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells was examined. EA.hy926 endothelial cells were seeded in the upper chambers of transwell plates, while SK-BR-3 cells overexpressing Ad-GFP or Ad-GFP-YB1 CTD were seeded in the lower chambers of transwell plates. EA.hy926 endothelial cells, which migrated through the Matrigel layer, were stained 10 h after beginning the experiment. In our study, Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells significantly inhibited chemotactic migration of EA.hy926 cells (Fig. 3B).

Next, conditioned media GFP-CM and GFP-YB1 CTD-CM were collected, and EA.hy926 endothelial cells were pretreated with GFP-CM and GFP-YB1 CTD-CM for 24 h; and then, seeded on Matrigel to determine tube formation. As shown in Fig. 3(C), tube length in GFP-YB1 CTD-CM-treated EA.hy926 cells were significantly shorter than GFP-CM-treated cells. Taken together, these results suggest that YB1 CTD inhibits SK-BR-3 breast cancer cell-induced angiogenesis in vitro.
YB1 CTD suppresses SK-BR-3 breast cancer cell-induced tumorigenicity and angiogenesis in vivo

SK-BR-3 tumour bearing nude mice model was established to further examine the antitumorigenic role of YB1 CTD. Naive Ad-GFP- or Ad-GFP-YB1 CTD-overexpressing SK-BR-3 breast cancer cells were subcutaneously injected into the right mammary fat pad of nude mice. Tumour growth was carefully monitored and size of tumour formation was measured every 2 days. Figure 4(A) shows SK-BR-3 breast cancer bearing mice at day 14 after injection. Weight of tumour-bearing mice and tumour growth curve are shown in Fig. 4(B and C). General status and weight of tumour-bearing mice have shown no significant difference among the three examined groups (Fig. 4B), while tumorigenicity and growth speed were much slower in the Ad-GFP-YB1 CTD group (Fig. 4C). Animals were sacrificed at day 14; and tumours were harvested, photographed and measured (Fig. 4D). Tumour volumes from naive SK-BR-3 and GFP groups were significantly larger than in the Ad-GFP-YB1 CTD group. There was no significant difference between naive SK-BR-3 cell and Ad-GFP-overexpressing SK-BR-3 cell groups (Fig. 4D). Taken together, these results suggest that overexpression of YB1 CTD in SK-BR-3 breast cancer cells attenuates SK-BR-3 cell ability to form tumours in nude mice.

To further identify the antiangiogenic role of YB1 CTD in SK-BR-3 tumour-bearing mice, immunohistochemistry was performed to examine VEGF and CD31 expressions, as well as angiogenesis in transplanted tumour tissues. VEGF staining showed lower VEGF levels and CD31 staining showed decreased angiogenesis in Ad-GFP-YB1 CTD-overexpressing SK-BR-3 xenograft transplants (Fig. 4E). Collectively, these findings suggest that YB1 CTD decreases VEGF levels and angiogenesis in SK-BR-3 tumour-bearing mice.

Discussion

Y-box-binding protein 1 is a prototypical member of the cold-shock domain (CSD) protein family. It is a multifunctional protein with an ancient CSD domain and intrinsically complex spatial structure, which allows its interactions with transcription factors, gene promoters and mRNAs [16]. These characteristics allow YB1 to participate in various cellular processes including gene transcription [14], mRNA translation [22] and DNA repair [23].
Several studies have demonstrated that YB1 expression levels are associated with aggressive tumour phenotype, poor prognosis and disease recurrence in a number of human malignancies [7,24,25]. However, YB1 might also exhibit prodifferentiation activities depending on cellular and gene context [13]. YB1 was reported to repress Chemokine ligand 5 (CCL5) transcription and promote macrophage differentiation [13]. In addition, YB1 binds to Matrix metalloproteinase-13 (MMP-13) promoter AP-1 site and represses MMP-13 expression, which is essential for cancer invasion [14].

In our previous study, we have demonstrated that YB1 binds to GC box in the promoter of Klf4, SM22α, p21 and cyclin D1; and promotes VSMC differentiation. Moreover, YB1-induced differentiation and inhibited apoptosis via CTD domain in vascular smooth muscle cells [20].

In this study, we sought to reveal the role of YB1 C-terminus in breast cancer proliferation and differentiation. Adenovirus vector harbouring YB1 CTD cDNA-coding region, lacking the ss-GC binding and Y-box-binding region, was constructed and infected into the SK-BR-3 breast cancer cell line. According to our results, YB1 CTD markedly decreased cell cycle-promoting factor cyclin B1 levels and increased cyclin-dependent kinase inhibitor p21 levels in SK-BR-3 breast cancer cells, which inhibited SK-BR-3 cell proliferation. Moreover, YB1 CTD also demonstrated the ability to disrupt cytoskeleton organization and slightly inhibits the migration of SK-BR-3 breast cancer cells.

Fig. 3. YB1 CTD inhibits VEGF expression and SK-BR-3 breast cancer cell-induced angiogenesis in vitro. (A) SK-BR-3 breast cancer cells were infected with Ad-GFP or Ad-GFP-YB1 CTD vectors for 24 h, media was removed, washed in DMEM with 0.5% FBS and incubated for an additional 24 h in DMEM with 0.5% FBS. GFP-overexpressing SK-BR-3-conditioned media (GFP-CM) and GFP-YB1 CTD-overexpressing SK-BR-3-conditioned media (GFP-YB1 CTD-CM) were collected, and VEGF expression in GFP-CM and GFP-YB1 CTD-CM were analysed by ELISA using human VEGF ELISA kit (Neobioscience Technoloty, China). Absorbance was measured at 450 nm. *P < 0.05 vs. GFP-CM group. (B) Transwell migration was examined using Boyden chamber assay. EA.hy926 endothelial cells (1 × 10⁵ per well) were seeded in the upper chamber of a Transwell plate in DMEM with 0.5% FBS. In the lower chamber, SK-BR-3 cells were infected with Ad-GFP or Ad-GFP-YB1 CTD for 48 h; then, trypsinized and seeded (1 × 10⁵ cells per well) in the lower chamber in DMEM with 0.5% FBS. EA.hy926 endothelial cells that migrated through the Matrigel layer were stained and quantified after 10 h. Cell invasion was photographed under a light microscope (Magnification, ×100): one representative experiment is shown (left); three independent experiments are summarized (right). *P < 0.05 vs. GFP group. (C) EA.hy926 endothelial cells were pretreated with GFP-CM and GFP-YB1 CTD-CM for 24 h. Subsequently, pretreated EA.hy926 cells (1 × 10⁵ per well) were seeded on Matrigel for 8 h. Representative photographs of tube formation are shown (upper, magnification ×40; lower, magnification ×100). Tube length was quantitated using IMAGE-PRO PLUS software (n = 5 per group). *P < 0.05 vs. GFP group.
either enhance or inhibit the DNA binding of other transcription factors [26]. A recent study about thermodynamic characterization of YB1 and nucleic acids interactions revealed that DNA binds with the most affinity to the C-terminal region (amino acids 130–219) of YB1 and indicated that binding of the multifunctional protein YB1 to nucleic acids regulates its biological behaviour [27]. Here, we found that YB1 CTD, lacking of N-terminal domain and CSD domain, has different functions from full-length YB1 in SK-BR-3 cells, which may due to its GC-box-binding activity in the target gene promoter [20].

Numerous studies have shown that tumours induce sprouting angiogenesis from surrounding vasculature, which is essential for tumour growth [2,28,29]. Our previous data have shown potential roles of YB1 CTD in proliferation and differentiation VSMCs, which are major components of vessel walls and play vital roles in vascular formation, remodelling and angiogenesis [20,30,31]. It was also reported that YB1 represses the vascular endothelial growth factor promoter in normoxic fibroblasts [32]. Another evidence revealed that YB1 can regulate tumour angiogenesis in YB1 expressing epithelial MDCK cells via release of secreted -modulators into the extracellular microenvironment [33]. In this study, we aimed to examine the function of YB1 CTD in SK-BR-3 breast cancer cell-induced angiogenesis. In order to determine the role of YB1

Fig. 4. YB1 CTD suppresses SK-BR-3 breast cancer cell-induced tumorigenicity and angiogenesis in vivo. (A) Naive SK-BR-3 breast cancer cells, GFP- or GFP-YB1 CTD-overexpressing SK-BR-3 breast cancer cells were subcutaneously injected into the right mammary fat pad of nude mice with 5 × 10⁶ cells per site. Mice were photographed 14 days after subcutaneous injection. (B) Weight of tumour-bearing mice was monitored every 2 days after subcutaneous injection. (C) Tumour volume was monitored every 2 days after subcutaneous injection, and tumour growth curve is shown. Tumour volume was calculated by the formula: \( V = \frac{1}{2} \times a \times b^2 \) (width). A two-way ANOVA and Bonferroni post-tests were done for the growth curve. *\( P < 0.05 \) vs. SK-BR-3 group. **\( P < 0.05 \) vs. Ad-GFP group. (D) Tumours were harvested from mice 14 days after subcutaneous injection and photographed. Volume of tumours were measured by the formula: \( V = \frac{1}{2} \times a \times b^2 \) (width). *\( P < 0.05 \) vs. Naive SK-BR-3 group. (E) Tumours from nude mice were fixed and sliced into 4 μm thick sections. CD31 and VEGF protein levels were detected by immunohistochemical staining; magnification ×200. Left, representative photographs; right, immunohistochemical staining scores. *\( P < 0.05 \) vs. Ad-GFP group.
CTD in antiangiogenic signalling in breast cancer cells, cellular and secreted VEGF in Ad-GFP-YB1 CTD-overexpressing SK-BR-3 cells were examined; and results demonstrated that YB1 CTD inhibited cellular and secreted VEGF expressions in SK-BR-3 breast cancer cells. Further experiments have shown that Ad-GFP-YB1 CTD overexpression in SK-BR-3 breast cancer cell inhibited SK-BR-3 cell-induced endothelial cell transwell migration and tube formation in vitro. Xenograft tumour model has shown that YB1 CTD suppressed tumorigenicity in vivo, and decreased angiogenesis in SK-BR-3 tumour-bearing mice.

In summary, in this study, we have presented the novel role of YB1 CTD in inhibiting breast cancer cell proliferation, migration and breast cancer-induced angiogenesis in vitro and in vivo. Our results points to a new breast cancer proliferation and angiogenesis regulatory mechanism, which provides novel avenues for therapies directed against angiogenesis.

Acknowledgements

This work is supported by the National Natural Science Foundation of China grant (No. 31301143), the Natural Science Foundation of Hebei Province grant (No. C2013201271) and the Hebei Youth Top-notch Talent Support Program.

Author contributions

J.-h.S. and B-p.C. conceived and designed the project, J.-h.S., N-p.C., S.W., M.-z.Z., B.W. and Y.-n.W. acquired the data, J.-h.S and N-p.C. analysed and interpreted the data and wrote the paper.

References

1. DeSantis C, Ma J, Bryan L and Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64, 52–62.
2. Alameddine RS, Otrock ZK, Awada A and Shamseddine A (2013) Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol 25, 313–324.
3. Das S, Singh G and Baker AB (2014) Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant coreceptors delivered by a liposomal system. Biomaterials 35, 196–205.
4. Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C and Studebaker AW (2014) Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer 14, 206.
5. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, Kim YG, Jang JY and Kim CW (2013) Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One 8, 84256.
6. Kosnopfel C, Sinnberg T and Schitteck B (2014) Y-box binding protein 1—a prognostic marker and target in tumour therapy. Eur J Cell Biol 93, 61–70.
7. Chatterjee M, Ranesco C, Stuhmer T, Eckstein N, Andrilis M, Gerecke C, Lorentz H, Royer HD and Bargou RC (2008) The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111, 3714–3722.
8. Guo T, Yu Y, Yip GW, Baeg GH, Thike AA, Lim TK, Tan PH, Matsumoto K and Bai HY (2015) Y-Box Binding Protein 1 is correlated with lymph node metastasis in intestinal type of gastric cancer. Histopathology 66, 491–499.
9. Imada K, Shiota M, Kohashi K, Kuroiwa K, Song Y, Sugimoto M, Naito S and Oda Y (2013) Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res 19, 4638–4650.
10. Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A and Nakopoulou L (2014) Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur J Surg Oncol 40, 289–296.
11. Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T, Kage M, Ono M, Kuwano M and Kumura T (2014) Nuclear Y-box-binding protein-I is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. Gynecol Oncol 132, 703–708.
12. Shibata T, Kan H, Murakami Y, Ureshino H, Watari K, Kawahara A, Kage M, Hattori S, Ono M and Kuwano M (2013) Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol Cancer Ther 12, 737–746.
13. Raffetseder U, Rauen T, Djudjaj S, Kretzler M, Bargou RC (2008) The Y-box binding protein YB-1 is a poor prognostic marker and target in tumor therapy. Eur J Cell Biol 93, 61–70.
14. Samuel S, Beifuss K and Bernstein LR (2007) YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site. BBA-biomembranes 1769, 525–531.
Inhibitory role of YB1 CTD in breast cancer  J.-h. Shi et al.

15 Evdokimova V, Tognon C, Ng T and Sorensen PH (2009) Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 8, 2901–2906.
16 Lyabin DN, Eliseeva IA and Ovchinnikov LP (2014) YB-1 protein: functions and regulation. WIREs RNA 5, 95–110.
17 Guryanov SG, Selivanova OM, Nikulin AD, Enin GA, Melnik BS, Kretov DA, Serdyuk IN and Ovchinnikov LP (2012) Formation of amyloid-like fibrils by Y-box binding protein 1 (YB-1) is mediated by its cold shock domain and modulated by disordered terminal domains. PLoS One 7, e36969.
18 Kloks CP, Spronk CA, Lasonder E, Hoffmann A, Vuister GW, Grzesiek S and Hilbers CW (2002) The solution structure and DNA-binding properties of the cold-shock domain of the human Y-box protein YB-1. J Mol Biol 316, 317–326.
19 Shi JH, Zheng B, Chen S, Ma GY and Wen JK (2012) Retinoic acid receptor alpha mediates all-trans-retinoic acid-induced Klf4 gene expression by regulating Klf4 promoter activity in vascular smooth muscle cells. J Biol Chem 287, 10799–10811.
20 Shi JH, Zheng B, Li YH, Sun Y, Han AL, Zhang XH, Lv XR, Chen S and Wen JK (2013) Novel insight into Y-box binding protein 1 in the regulation of vascular smooth muscle cell proliferation through targeting GC box-dependent genes. FEBS Lett 587, 1326–1332.
21 Shav D, Gottlieb R, Zaretksy U, Elad D and Einav S (2014) Wall shear stress effects on endothelial-endothelial and endothelial-smooth muscle cell interactions in tissue engineered models of the vascular wall. PLoS One 9, e88304.
22 Lyabin DN, Nigmatullina LF, Doronin AN, Eliseeva IA and Ovchinnikov LP (2013) Identification of proteins specifically interacting with YB-1 mRNA 3’ UTR and the effect of hnRNP Q on YB-1 mRNA translation. Biochemistry (Moscow) 78, 651–659.
23 Kim ER, Selyutina AA, Buldakov IA, Evdokimova V, Ovchinnikov LP and Sorokin AV (2013) The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress. Cell Cycle 12, 3791–3803.
24 Fujiwara-Okada Y, Matsumoto Y, Fukushima J, Setsu N, Matsuura S, Kamura S, Fujiwara T, Iida K, Hatano M and Nabeshima A et al. (2013) Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Brit J Cancer 108, 836–847.
25 Fushimi F, Taguchi K, Izumi H, Kohno K, Kuwano M, Ono M, Nakashima Y, Takesue T, Naito S and Oda Y (2013) Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma. Virchows Arch 463, 553–562.
26 Kohno K, Izumi H, Uchiiumi T, Ashizuka M and Kuwano M (2003) The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25, 691–698.
27 Tanabe Y, Nagatoishi S and Tsumoto K (2015) Thermodynamic characterization of the interaction between the human Y-box binding protein YB-1 and nucleic acids. Mol BioSyst 11, 2441–2448.
28 Zhou W, Wang G and Guo S (2013) Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells. BBA 1836, 304–320.
29 Koutras AK, Starakis I, Lymperatou D and Kalofonos HP (2012) Angiogenesis as a therapeutic target in breast cancer. Mini-Rev Med Chem 12, 1230–1238.
30 Jing L, Peng X, Xie MJ, Yu ZY and Wang W (2014) Different responses of cell cycle between rat vascular smooth muscle cells and vascular endothelial cells to paclitaxel. J Huazhong U Sci Med 34, 370–375.
31 Korn C, Scholz B, Hu J, Srivastava K, Wojtowicz J, Arnspirger T, Adams RH, Boutros M, Augustin HG and Augustin I (2014) Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogenesis. Development 141, 1757–1766.
32 Coles LS, Diamond P, Lambrusco L, Hunter J, Burrows J, Vadas MA and Goodall GJ (2002) A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic fibroblasts. Nucleic Acids Res 30, 4845–4854.
33 Gopal SK, Greeneing DW, Mathias RA, Ji H, Rai A, Chen M, Zhu HJ and Simpson RJ (2015) YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment. Oncotarget 6, 13718–13730.